1858 Wealth Management’s AbbVie ABBV Stock Holding History

1858 Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$743K	Sell	3,207 -195	-6%	-$39.7K	0.52%	46
2025 Q2	$631K	Sell	3,402 -307	-8%	-$57.1K	0.47%	47
2025 Q1	$777K	Sell	3,709 -814	-18%	-$158K	0.66%	47
2024 Q4	$804K	Buy	4,523 +381	+9%	+$70K	0.64%	48
2024 Q3	$818K	Sell	4,142 -149	-3%	-$27.8K	0.67%	48
2024 Q2	$736K	Sell	4,291 -103	-2%	-$17.1K	0.61%	50
2024 Q1	$681K	Hold	4,394	–	–	0.65%	49
2023 Q4	$681K	Buy	+4,394	New	+$641K	0.65%	49

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

1858 Wealth Management's ABBV Position: Q3 2025 in Review

1858 Wealth Management reduced its AbbVie (ABBV) stake by 5.7% in Q3 2025, selling an estimated $39.7K and leaving 3,207 shares worth $743K. The position accounts for 0.52% of the portfolio, ranked #46.

1858 Wealth Management first reported a position in ABBV in Q4 2023 and has held it in 8 quarters since. The position peaked at $818K in Q3 2024. 3,906 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

1858 Wealth Management held 3,207 shares of AbbVie worth $743K as of Q3 2025.
1858 Wealth Management sold 195 AbbVie shares in Q3 2025, an estimated $39.7K.
AbbVie made up 0.52% of 1858 Wealth Management's portfolio in Q3 2025, its #46 holding.
1858 Wealth Management first reported a position in AbbVie in Q4 2023 and has held it in 8 quarters since.
1858 Wealth Management's AbbVie position peaked at $818K in Q3 2024.
3,906 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on 1858 Wealth Management's 13F filing for Q3 2025, filed 14 Nov 2025.